Related Experiment Video

Updated: Aug 31, 2025

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.0K

Efficacy of ticagrelor compared to clopidogrel in improving endothelial function in patients with coronary artery

Muayad Saud Albadrani1, Amal Mohamed Elhusein2, Yasir Abdullah Alotaibi2

  • 1College of Medicine, Taibah University, Madena.

Journal of Cardiovascular Medicine (Hagerstown, Md.)
|August 22, 2022
PubMed

Insights

Ticagrelor shows superior endothelial function improvement compared to clopidogrel in coronary artery disease patients. This includes better progenitor cell levels and reduced apoptosis, indicating enhanced vascular health.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Vascular Biology

Background:

  • Ticagrelor and clopidogrel are P2Y12 receptor inhibitors used as antiplatelet agents.
  • Previous research has explored their comparative effects on endothelial function.

Purpose of the Study:

  • To systematically review and compare the efficacy of ticagrelor versus clopidogrel in enhancing endothelial function.
  • Focus on patients diagnosed with coronary artery disease (CAD).

Main Methods:

  • Systematic literature search of Scopus, PubMed, Web of Science, and Cochrane Library in August 2021.
  • Inclusion of randomized controlled trials comparing ticagrelor and clopidogrel in CAD patients for endothelial function improvement.

Main Results:

  • Seven trials (n=511) were analyzed.
  • Ticagrelor significantly increased progenitor cells (CD34+KDR+, CD34+133+) and nitric oxide levels.
  • Ticagrelor demonstrated a lower rate of endothelial cell apoptosis and improved levels of reactive oxygen species and soluble P-selectin.
  • Flow-mediated dilation results were inconsistent across studies.

Conclusions:

  • Ticagrelor appears to offer additional benefits for endothelial function compared to clopidogrel.
  • Findings suggest ticagrelor may be more effective in improving vascular health in CAD patients.
Abstract

More Related Videos

Assessing Endothelial Vasodilator Function with the Endo-PAT 200007:46

Assessing Endothelial Vasodilator Function with the Endo-PAT 2000

Published on: October 15, 2010

43.8K
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

5.2K

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
621
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
28
Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
4.8K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
24
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
248